IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation

Journal of Clinical Investigation

Volumn 104, Issue 3, 1999, Pages 317-325

  Teshima, Takanori ^a   Hill, Geoffrey R ^b   Pan, Luying ^b   Brinson, Yani S ^b   Van Den Brink, Marcel R M ^b,c   Cooke, Kenneth R ^b   Ferrara, James L M ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 11;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ARTICLE; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOCOMPATIBILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032701975     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI7111     Document Type: Article

References (49)

1. Bortin, M., Rimm, A., and Saltzstein, E. 1973. Graft-versus-leukemia: Quantification of adoptive immunotherapy in murine leukemia. Science. 173:811-813.
2. Truitt, R.J., and Johnson, B.D. 1995. Principles of graft versus leukemia reactivity. Bone Marrow Transplant. 1:61-68.
3. Barrett, A.J, 1997. Mechanisms of the graft-versus-leukemia reaction. Stem Cells. 15:248-258.
4. Barnes, D., Corp, M., Loutit, J., and Neal, F. 1956. Treatment of murine leukaemia with x-rays and homologous bone marrow: preliminary communication. Br. Med. J 2:626-630.
5. Horowitz, M.M., et al. 1990. Graft-verus-leukemia reactions after bone marrow transplantation. Blood. 75:555-562.
6. Apperley, J.F., Jones, L., Hale, G., and Goldman, J.M. 1986. Bone marrow transplantation for chronic myeloid leukemia: T-cell depletion with Campath-1 reduces the incidence of acute graft-versus-host disease but may increase the risk of leukemia relapse. Bone Marrow Transplant. 1:53-66.
7. Krenger, W., Hill, G.R., and Ferrara J.L.M. 1997. Cytokine cascades in acute graft-versus-host disease. Transplantation. 64:553-558.
8. Kichian, K., Nestel, F.P., Kim, D., Ponka, P., and Lapp, W.S. 1996. IL-12 p40 messenger RNA expression in target organs during acute graft-versus-host disease. Possible involvement of IFN-gamma. J. Immunol. 157:2851-2856.
9. Nestel, F.P., Price, K.S., Seemayer, T.A., and Lapp, S.W. 1992. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J. Exp. Med. 175:405-413.
10. Du, X., and Williams, D.A. 1997. Interleukin IL-11: review of molecular, cell biology, and clinical use. Blood. 11:3897-3908.
11. Du, X.X., Neben, T., Goldman, S., and Williams, D.A. 1993. Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice: acceleration of recovery of peripheral blood neutrophils and platelets. Blood. 81:27-34.
12. Tepler, I., et al. 1996. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 87:3607-3614.
13. Qui, B.S., Pfieffer, C.J., and Keith, J.C. 1996. Protection by recombinant interleukin-11 against experimental TNB-induced colitis. Dig. Dis. Sci. 41:1625-1630.
14. Trepicchio, W.L., Bozza, M., Pedneault, G., and Dorner, A.J. 1996. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J. Immunol. 157:3627-3634.
15. Trepicchio, W.L., Wang, L., Bozza, M.,and Dorner, A.J. 1997. Interleukin-11 regulates macrophage effector function through the inhibition of NF-kB. J. Immunol. 159:5661-5671.
16. Hill, G.R., et al. 1998. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 102:115-123.
17. Morse, H.C., Shen, F.W., and Hammerling, U. 1987. Genetic nomenclature for loci controlling mouse lymphocyte antigens. Immunogenetics. 25:71-78.
18. Cooke, K.R., et al. 1996. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood. 88:3230-3239.
19. Paul, S.R., Barut, B.A., Bennett, F., Cochtan, M.A., and Anderson, K.C. 1992. Lack of a role of interleukin-11 in the growth of multiple myeloma, Leuk. Res. 16:247-252.
20. Matulonis, U., Salgia, R., Okuda, K., Druker, B., and Griffin, J.D. 1993. Interleukin-3 and p210 bcr/abl activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp. Hematol. 21:1460-1466.
21. Kappler, J., White, J., Wegmann, D., Mustain, E., and Marrack, P. 1982. Antigen presentation by 1a+ B cell hybridomas to H-2-restricted T cell hybridomas. Proc. Natl. Acad. Sci. USA. 79:3604-3607
22. Korngold, R., and Sprent, J. 1985. Surface markers of T cells causing lethal graft-vs-host disease to class I vs. class II H-2 differences. J. Immunol. 135:3004-3010.
23. Antin, J.H., and Ferrara, J.LM. 1992. Cytokine dysregulation and acute graft-versus-host disease. Blood. 80:2964-2968.
24. Pietryga, D.W., Blazar, B.R., Soderling, C.C., and Vallera, D.A. 1987. The effect of T subset depletion on the incidence of lethal graft-versus-host disease in a murine major-histocompatibility-complex-mismatched transplantation system. Transplantation. 43:442-445.
25. Sprent, J., Schaefer, M., Gao, E.K., and Korngold, R. 1988. Role of T-cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 different hosts. J. Exp. Med. 167:556-569.
26. Sykes, M., Abraham, V.S., Harty, M.W., and Pearson, D.A. 1993. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J. Immunol. 150:197-205.
27. Yang, Y., et al. 1997. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood. 90:4651-4660.
28. Faber, L.M., van Luxemburg-Heijs, W.S., Veenhof A.F., Willemze, R., and Falkenburg, J.H. 1995. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood. 86:2821-2828.
29. Graubert, T.A., DiPersio, J.F., Russell, J.H., and Ley, T.J. 1997. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J. Clin. Invest. 100:904-911.
30. Hill, G.R., et al. 1997. Total body irradiation and acute graft versus host disease. The role of gastrointestinal damage and inflammatory cytokines. Blood. 90:3204-3213.
31. Wiley, S.R., et al. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673-682.
32. Snell, V., et al. 1997. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br. J. Haematol. 99:618-624.
33. Kayagaki, N., et al. 1999. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J. Immunol. 162:2639-2647.
34. + cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood. 83:2560-2569.
35. Lichtenheld, M.G., et al. 1988. Structure and function of human perform. Nature. 335:448-451.
36. Kägi, D., et al. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 369:31-37.
37. + T cell-mediated cytotoxicity. J. Immunol. 152:1127-1133.
38. Ju, S.T., Cui, H., Panka, D.J., Ettinger, R., and Marshak-Rothstein, A. 1994. Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc. Natl. Acad. Sci. USA. 91:4185-4189.
39. Lowin, B., Hahne, M., Mattmann, C., and Tschopp, J. 1994. Cytolytic T-cell cytotoxiciry is mediated through perforin and Fas lytic pathways. Nature. 370:650-652.
40. Suda, T., et al. 1995. Expression of the Fas ligand in cells of T cell lineage. J. Immunol. 154:3806-3813.
41. Lee, RK., Spielman, J., Zhao, D.Y., Olsen, K.J., and Podack, E.R. 1996. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J. Immunol. 157:1919-1925.
42. Graubert, T.A., Russell, J.H., and Ley, T. 1996. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood. 87:1232-1237.
43. + T cells each can use a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation. 64:571-576.
44. Hattori, K., et al. 1998. Differential effects of anti-Fas ligand and anti-tumor necrosis factor-a antibodies on acute graft-versus-host disease pathologies. Blood. 91:4051-4055.
45. Tsukada, N., Kobata, T., Aizawa, Y., Yagita, H., and Okumura, K. 1999. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood. 93:2738-2747.
46. Shima, Y., et al. 1995. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood. 85:757-764.
47. van den Broek, M.F., et al. 1996. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184:1781-1790.
48. Owen-Schaub, L.B., Radinsky, R., Kruzel, E., Berry, K., and Yonehara, S. 1994. Anti-Fas on nonhematopoietic tumors: levels of Fas/Apo-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 54:1580-1586.
49. Keane, M.M., Ettenberg, S.A., Lowery, G.A., Russell, S., and Lipkowicz, S. 1996. Fas expression and function in normal and malignant breast cell lines. Cancer Res. 56:4791-4798.